North America Prescription Digital Therapeutics (PDTx) Market, By Mechanism (Input Mechanisms, Output Mechanisms), Category (Medication Augmentation, Medication Replacement), Treatment (Outpatient Treatment, Monotherapy), Software (Software For Respiratory Conditions, Software For Mental Health, Software For Opioid Use Disorder, Software For Diabetes, Others), Services (Behavioral Microservices, Medical Microservices), App Accessibility (Android, iOS, Windows), App Type (Native Apps, Web Apps), Application (Substance Use Disorder (SUD), Opioid Use Disorder (OUD), Attention Deficit/Hyperactivity Disorder (ADHD), Alzheimer’s Disease, Major Depressive Disorder (MDD), Insomnia, Epilepsy, Movement Disorder, Multiple Sclerosis, Migraine, Autism Spectrum Disorder, Oncology, Inflammation, Respiratory, Cardiovascular, Pain Management, Metabolic Conditions, Others), Patients (Children, Adults) – Industry Trends and Forecast to 2030.
North America Prescription Digital Therapeutics (PDTx) Market Analysis and Size
Growing smartphone penetration in developed & developing countries is inculcating the adoption of prescription digital therapeutics (PDTx). It is developed as a boon for a number of diseases such as ADHD, major depressive disorder (MDD), opioid use disorder (OUD), substance use disorder (SUD), autism spectrum disorder, multiple sclerosis, and cardiovascular disease. According to National Center for Chronic Disease Prevention and Health Promotion, 6 in 10 American adults suffer from a chronic disease, whereas 4 out of 10 adults have 2 or more chronic diseases. Currently, numerous research & clinical studies are going on which is anticipated to create a competitive advantage for numerous manufacturers to develop new and innovative technology.
Data Bridge Market Research analyses a growth rate in the prescription digital therapeutics (PDTx) market in the forecast period 2023-2030. The expected CAGR of prescription digital therapeutics (PDTx) market is tend to be around 22% in the mentioned forecast period. The market is valued at USD 751.58 million in 2022, and it would grow upto USD 3688.53 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America Prescription Digital Therapeutics (PDTx) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Mechanism (Input Mechanisms, Output Mechanisms), Category (Medication Augmentation, Medication Replacement), Treatment (Outpatient Treatment, Monotherapy), Software (Software For Respiratory Conditions, Software For Mental Health, Software For Opioid Use Disorder, Software For Diabetes, Others), Services (Behavioral Microservices, Medical Microservices), App Accessibility (Android, iOS, Windows), App Type (Native Apps, Web Apps), Application (Substance Use Disorder (SUD), Opioid Use Disorder (OUD), Attention Deficit/Hyperactivity Disorder (ADHD), Alzheimer’s Disease, Major Depressive Disorder (MDD), Insomnia, Epilepsy, Movement Disorder, Multiple Sclerosis, Migraine, Autism Spectrum Disorder, Oncology, Inflammation, Respiratory, Cardiovascular, Pain Management, Metabolic Conditions, Others), Patients (Children, Adults)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America
|
|
Market Players Covered
|
ResMed (U.S.), SAMSUNGHEALTHCARE (South Korea), Biofourmis (U.S.), Novartis AG (Switzerland), Medtronic (Ireland), Pear Therapeutics, Inc. (U.S.), Voluntis (France), Omada Health, Inc. (U.S.), GAIA AG (Germany), Welldoc’s Bluestar (U.S.), Solera Network (U.S.), Akili Interactive Labs, Inc. (U.S.), Better Therapeutics, LLC (U.S.), BigHealth (U.S.), Biofourmis (U.S.), Click Therapeutics, Inc. (U.S.), Happify, Inc. (U.S.), Limbix Health, Inc. (U.S.), Naturalcycles Nordic AB (Sweden), NuvoAir AB (Sweden), Sensyne Health plc. (U.K.), Xealth (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Prescription digital therapies is a kind of software that is used to treat numerous ailments. Artificial intelligence, diverse algorithms, and virtual reality are widely used to develop these therapeutic instruments. Patients sometimes use prescription digital therapeutics software and services to get any form of treatment they needed it. These medicines are closely regulated by the FDA and other regulatory authorities and can only be used with an appropriate prescription from a doctor.
North America Prescription Digital Therapeutics (PDTx) Market Dynamics
Drivers
- Increasing Regulatory Initiatives
Rising regulatory initiatives are estimated to boost standardization and R&D in the market during the forecast period. For instance, the Software Pre-Cert Pilot Program which is a part of the Digital Health Innovation Action Plan of the FDA, planned for a more efficient regulatory oversight of Software-based Medical Devices (SaMD) developed by manufacturers. The main aim is to develop an efficient regulatory oversight for evaluating organizations to establish trust that they can develop high-quality SaMD products. Therefore, this factor increases the growth of the market.
- Huge Role in Managing Respiratory Diseases
The increasing adoption of digital therapeutic products for managing respiratory diseases is boosting the market growth. These products include BreatheSmart by Cohero Health, Respiro by Amiko, Propeller by Propeller Health, Hailie by Adherium, and CareTRx by Teva. Digital therapeutics helps to transform the treatment course of COPD and asthma as poor medication adherence is a big issue for treating respiratory diseases. Digital therapeutic solutions can help a lot in this regard. This factor improves the market growth.
Opportunities
- Increased Research Activities
The research activities associated with the prescription digital therapeutics is increasing and thus boosting the market's growth. For instance, NuvoAir AB was certified as Class Im medical device in August 2020. The company has achieved this certification due to its advanced features involving certified bluetooth spirometer, combined with the healthcare portal and connected patient app. This certification has improved the brand value among the physicians and patients. Thus, this factor created much opportunity for the market growth.
- Increased Mergers and Acquisitions
The number of mergers and acquisitions has grown in the recent years which is increasing the market growth. For instance, Teladoc expanded its partnership with the National Labor Alliance in December 2021 for providing its full suite of virtual care products and services. It includes general medical, expert medical services, specialty care, virtual primary care programs, mental health, and chronic condition management. Thus, this factor helps in the market expansion.
Restraints/Challenges
- Difficulty in Adaptation of Digital Therapeutics by Doctors
Not all doctors and providers are not familiar with the increasing digitization. Doctors and healthcare professionals should get familiar with digital therapy solutions before using their mass adoption. They should analyze the results of clinical trials before recommending the solutions to their patients. To perform this, few DTx companies opt for pharmaceutical model wherein partnerships with distributors are used to inform doctors about clinical trial results, new solutions, and decisions. Thus, this hampers the market growth.
This prescription digital therapeutics (PDTx) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prescription digital therapeutics (PDTx) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2019, Welldoc Inc., announces the development and commercialization of BlueStar to East Asia with Japan based Astellas Inc. Under the agreement, Astellas and Welldoc will jointly develop and commercialize BlueStar in Japan and certain other Asian markets for patients with diabetes, collaborate to widen the adoption of BlueStar.
North America Prescription Digital Therapeutics (PDTx) Market Scope
The prescription digital therapeutics (PDTx) market is segmented on the basis of mechanism, category, treatment, software, services, app accessibility, app type, application, patients. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Mechanism
- Input Mechanisms
- Output Mechanisms
Category
- Medication Augmentation
- Medication Replacement
Treatment
- Outpatient Treatment
- Monotherapy
Software
- Software for Respiratory Conditions
- Software for Mental Health
- Software for Opioid Use Disorder
- Software for Diabetes
- Others
Services
- Behavioral Microservices
- Medical Microservices
App Accessibility
- Android
- iOS
- Windows
App Type
- Native Apps
- Web Apps
Application
- Substance Use Disorder (SUD)
- Opioid Use Disorder (OUD)
- Attention Deficit/Hyperactivity Disorder (ADHD)
- Alzheimer’s Disease
- Major Depressive Disorder (MDD)
- Insomnia
- Epilepsy
- Movement Disorder
- Multiple Sclerosis
- Migraine
- Autism Spectrum Disorder
- Oncology
- Inflammation
- Respiratory
- Cardiovascular
- Pain Management
- Metabolic Conditions
- Others
Patients
- Children
- Adults
Prescription Digital Therapeutics (PDTx) Market Regional Analysis/Insights
The prescription digital therapeutics (PDTx) market is analyzed and market size insights and trends are provided by mechanism, category, treatment, software, services, app accessibility, app type, application, patients as referenced above.
The major countries covered in the prescription digital therapeutics (PDTx) market report are U.S., Canada and Mexico in North America.
U.S. is anticipated to grow with the highest CAGR in the forecast period due to the increased adoption of prescription digital therapeutics (PDTx) by the patients in this region. Also, increased presence of major market players in the region and the launch of multiple products boosts the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Prescription Digital Therapeutics (PDTx) Market Share Analysis
The prescription digital therapeutics (PDTx) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to prescription digital therapeutics (PDTx) market.
Key players operating in the prescription digital therapeutics (PDTx) market include:
- ResMed (U.S.)
- SAMSUNGHEALTHCARE (South Korea)
- Biofourmis (U.S.)
- Novartis AG (Switzerland)
- Medtronic (Ireland)
- Pear Therapeutics, Inc. (U.S.)
- Voluntis (France)
- Omada Health, Inc. (U.S.)
- GAIA AG (Germany)
- Welldoc’s Bluestar (U.S.)
- Solera Network (U.S.)
- Akili Interactive Labs, Inc. (U.S.)
- Better Therapeutics, LLC (U.S.)
- BigHealth (U.S.)
- Biofourmis (U.S.)
- Click Therapeutics, Inc. (U.S.)
- Happify, Inc. (U.S.)
- Limbix Health, Inc. (U.S.)
- Naturalcycles Nordic AB (Sweden)
- NuvoAir AB (Sweden)
- Sensyne Health plc. (U.K.)
- Xealth (U.S.)
SKU-